Trial Profile
A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Granulocyte-macrophage colony-stimulating factors (Primary) ; TPIV 200 (Primary)
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 21 Jan 2021 Status changed from active, no longer recruiting to completed.
- 02 Mar 2020 Planned End Date changed from 1 May 2020 to 1 May 2021.
- 02 Mar 2020 Planned primary completion date changed from 1 May 2020 to 1 May 2021.